An anti-interleukin-1 (anti-IL-1) alpha antibody called MABp1 has been shown to significantly improve response in patients with metastatic colorectal cancer (mCRC) in a phase III clinical trial that adopted symptom control as criteria for objective response (OR).
Regorafenib significantly improves overall survival (OS) and progression-free survival (PFS) in patients with intermediate or advanced hepatocellular carcinoma (HCC) whose disease progressed on sorafenib treatment, according to results of the phase III RESOURCE trial presented at the European Society for Medical Oncology (ESMO) 18th World Congress on Gastrointestinal Cancer.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
The use of the sodium/glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin in patients with type 2 diabetes (T2D) and moderate renal impairment provides benefits beyond glucose lowering, with no new safety signals, in the phase III DERIVE* study.